Press release
Alzheimer's Disease in Major Market is projected to grow to USD 16.20 billion by 2030
Alzheimer's Disease in Major
The market is projected to grow to USD 16.20 billion by 2030, expanding at a CAGR of 15.2%, fueled by pipeline launches like Donanemab, next-generation tau therapies, early-diagnosis imaging solutions, and wider reimbursement support.
Demand is also supported by rising prevalence: ~18.7 million AD patients across major markets in 2023, expected to exceed 22.4 million by 2030.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73642
Key Market Drivers
• Strong launch trajectory of disease-modifying therapies (DMTs) such as lecanemab and donanemab.
• Rising aging population across the US, Europe, and Japan.
• Increase in early diagnosis enabled by PET imaging, CSF analysis, and blood-based biomarkers.
• Favorable regulatory pathways, including accelerated approvals by FDA and EMA.
• Growing investment in clinical R&D for anti-tau therapies and neuroprotective agents.
• Expansion of reimbursement coverage for DMTs, especially in the U.S. Medicare system.
Market Restraints
• High cost of biologics, limiting affordability in several markets.
• Complex safety management requirements (e.g., ARIA monitoring with MRI).
• Limited trained neurologists and infusion centers in certain regions.
• Low awareness and underdiagnosis in early-stage patients.
• Stringent regulatory scrutiny for new therapeutic classes.
Market Segmentation
By Drug Class
• Cholinesterase Inhibitors
• NMDA Receptor Antagonists
• Amyloid Beta Inhibitors (mAbs)
• Tau Protein Inhibitors (Emerging)
• Combination Therapies (Pipeline)
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics / Infusion Centers
By Disease Stage
• Mild AD
• Moderate AD
• Severe AD
• Early/MCI (Mild Cognitive Impairment)
Regional Insights
United States
• 2023 market size: USD 3.85 billion
• Strong uptake of Lecanemab following Medicare coverage expansion.
• 2030 forecast: USD 10.8 billion, fastest-growing major market.
• Widespread adoption of blood-based biomarkers for screening.
EU5 (Germany, France, Italy, Spain, UK)
• 2023 market size: USD 1.65 billion
• Uptake slower due to controlled reimbursement for DMTs.
• 2030 forecast: USD 4.1 billion
• Expanded use of PET imaging and CSF diagnostic tools.
Japan
• 2023 market size: USD 0.45 billion
• High aging population supports growth.
• 2030 forecast: USD 1.30 billion
• Government initiatives toward dementia prevention driving adoption.
Explore Full Report here: https://exactitudeconsultancy.com/reports/73642/alzheimer-s-disease-in-major-market
Competitive Landscape (20 Key Companies)
1. Biogen - Aducanumab
2. Eisai Co. Ltd. - Lecanemab
3. Eli Lilly - Donanemab (pipeline)
4. Roche/Genentech - Gantenerumab
5. Novartis AG
6. Pfizer Inc.
7. Merck & Co.
8. Johnson & Johnson
9. AbbVie
10. AC Immune SA - anti-tau pipeline
11. AstraZeneca
12. Grifols
13. Lundbeck
14. Otsuka Holdings
15. Takeda Pharmaceuticals
16. Alzheon Inc. - ALZ-801
17. Anavex Life Sciences
18. BioVie Inc.
19. Cassava Sciences - Simufilam
20. Axsome Therapeutics
Recent Developments
• 2024: FDA panel backs donanemab, improving chances for 2025 approval.
• 2024: Blood-based p-tau217 tests gain widespread clinical adoption in U.S.
• 2023-2024: Eisai and Biogen expand infusion center partnerships for Lecanemab.
• 2024: Roche reports next-phase trial data for next-generation anti-amyloid agents.
• 2023: Japan announces revised dementia care pathway including biomarker testing.
• EU5: Deployment of AI-enabled imaging tools for early MCI detection.
Opportunities
• High unmet need in early-stage and preclinical AD.
• Significant scope for home-based biomarker testing kits (p-tau).
• Growth potential in digital therapeutics (DTx) for cognitive assessment.
• Pipeline expansion in tau-targeted immunotherapies.
• AI-diagnostics to reduce diagnostic delays.
Conclusion
The Alzheimer's Disease market in major global markets is entering a high-growth phase, driven by transformative treatment technologies, broader diagnostic adoption, and an expanding patient population. With a CAGR of 15.2% through 2030, the arrival of DMTs represents one of the most significant breakthroughs in neurology, unlocking strong commercial opportunities for biopharma companies. The U.S. will remain the dominant growth engine, while Europe and Japan will scale with reimbursement reforms and aging populations.
This report is also available in the following languages : Japanese (主要市場におけるアルツハイマー病), Korean (주요 시장의 알츠하이머병), Chinese (阿尔茨海默病在主要市场), French (La maladie d'Alzheimer sur les principaux marchés), German (Alzheimer-Krankheit in einem wichtigen Markt), and Italian (La malattia di Alzheimer nel mercato principale), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/73642
Our More Reports:
Memory Disorders Market
https://exactitudeconsultancy.com/reports/71948/memory-disorders-market
Alzheimer's Disease Market
https://exactitudeconsultancy.com/reports/72097/alzheimer-s-disease-market
Alzheimer's Disease Patient Pool Analysis, Market
https://exactitudeconsultancy.com/reports/72123/alzheimer-s-disease-patient-pool-analysis-market
Alzheimers Disease in 68 Market
https://exactitudeconsultancy.com/reports/73641/alzheimers-disease-in-68-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer's Disease in Major Market is projected to grow to USD 16.20 billion by 2030 here
News-ID: 4294360 • Views: …
More Releases from Exactitude Consultancy
Bioprocess Analyzers Market to Reach USD 6.75 Billion by 2030 expanding at a CAG …
Innovation
Sub-Headline: The global Bioprocess Analyzers Market is projected to grow from USD 3.42 billion in 2023 to USD 6.75 billion by 2030, expanding at a CAGR of 9.8%, fueled by the increasing demand for biologics, cell & gene therapies, and real-time process monitoring.
Introduction
The Bioprocess Analyzers Market is witnessing strong acceleration as biopharmaceutical manufacturing becomes increasingly complex, regulated, and data-driven. Bioprocess analyzers-which measure critical parameters such as pH, dissolved oxygen, glucose,…
DNA Methylation Market Set to Reach USD 3.85 Billion by 2030,at a CAGR of 11.9%.
Sub-Headline: Driven by breakthroughs in cancer diagnostics, personalized medicine, and liquid biopsy technologies, the global DNA Methylation Market is projected to grow from USD 1.72 billion in 2023 to USD 3.85 billion by 2030, at a CAGR of 11.9%.
Introduction
The DNA Methylation Market is experiencing a major expansion as epigenetics becomes central to cancer detection, drug discovery, and precision medicine. DNA methylation-an essential epigenetic mechanism that regulates gene expression without changing…
Glycated Haemoglobin Testing Market Surges to USD 3.10 Billion by 2030, growing …
Glycated Haemoglobin Testing Market Surges to USD 3.10 Billion by 2030 as Diabetes Cases Accelerate Globally | Abbott, Roche, Siemens Take the Lead
Sub-Headline: Rising diabetes prevalence, rapid adoption of point-of-care devices, and technological advancements in HbA1c analyzers are pushing the global market from USD 1.65 billion in 2023 to USD 3.10 billion by 2030, growing at a CAGR of 9.2%.
Introduction
The Glycated Haemoglobin (HbA1c) Testing Market is witnessing strong global momentum…
PFAS Testing Market to Reach USD 2.95 Billion by 2030,at a CAGR of 10.4%.
Sub-Headline: Rising environmental contamination, stringent government regulations, and expanding laboratory capacity are driving the PFAS Testing Market from USD 1.48 billion in 2023 to USD 2.95 billion by 2030, at a CAGR of 10.4%.
Introduction
The PFAS Testing Market is experiencing robust global growth as governments, environmental agencies, and industrial sectors intensify efforts to identify and remediate contamination caused by per- and polyfluoroalkyl substances (PFAS). Known as "forever chemicals," PFAS compounds persist…
More Releases for Alzheimer
Alzheimer Therapeutics Market Breakthrough Innovations and Increasing Treatment …
The Alzheimer Therapeutics Market is rapidly evolving as disease-modifying therapies, early-stage diagnostic tools, and biomarker-driven treatment approaches reshape global management of Alzheimer's disease (AD). As one of the most prevalent neurodegenerative conditions, Alzheimer's affects millions of older adults worldwide. With recent regulatory approvals of anti-amyloid monoclonal antibodies, enhanced imaging technology, and increased R&D investment, the market is experiencing unprecedented momentum.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/51928
Key Takeaways
• Disease-modifying…
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
